Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T19:10:32.285Z.
Calculation as of: 2026-10-06T19:10:32.285Z.
Quote observation: 2026-10-06T19:10:16.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 465112d98a6c82939a581bc37d9e1b887570666ec45509b145499b9afd19c223
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$53.55M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$53.93M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$51.19M
EV/EBIT Ratio
N/A
TTM Avg
0.77x
3Y Avg
0.98x
5Y Avg
0.98x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aldeyra The (ALDX) | $53.29M | N/A | N/A | N/A | N/A |
| NOMAD Power Solutions, Inc. (NMAD)vs › | $53.15M | N/A | N/A | N/A | N/A |
| Zhengye Biotechnology Holding Limited (ZYBT)vs › | $53.55M | N/A | N/A | N/A | N/A |
| ImageneBio Inc (IMA)vs › | $53.01M | N/A | N/A | N/A | N/A |
| Spectral AI, Inc. (MDAI)vs › | $53.62M | N/A | N/A | N/A | N/A |
| Rani Therapeutics Holdings, Inc. (RANI)vs › | $53.93M | N/A | N/A | N/A | N/A |
| biote Corp. (BTMD)vs › | $51.61M | 11.46x | 6.17x | 6.96x | 6.04x |
| eXoZymes, Inc. (EXOZ)vs › | $51.51M | N/A | N/A | N/A | N/A |
| Tenax Therapeutics, Inc. (TENX)vs › | $51.19M | N/A | 0.77x | 0.98x | 0.98x |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $51.72M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
